Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1

31 Dec 2005

Abstract excerpt

Biological activity of interferon-beta (IFNbeta) can be assessed by measuring IFN-stimulated genes (ISGs). Among them, myxovirus resistance protein A (MxA) appears to have the highest specificity, but it has no role in the pathogenesis of multiple sclerosis (MS). To investigate the reliability of MxA as a biomarker, we compared its expression to that of two other ISGs: TNF-related apoptosis-inducing ligand...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to interferon and immune responses
Share to Multiple Sclerosis Research Studies
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16459719
DOI: 10.1191/135248506ms1245oa

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1PMID 16459719Read ↗

Search for Specific Biomarkers of IFNβ Bioactivity in Patients with Multiple SclerosisSemantic proximity Read ↗

Identification of new sensitive biomarkers for the <i>in vivo</i> response to interferon‐β treatment in multiple sclerosis using DNA‐array evaluationSemantic proximity Read ↗

Gene expression analysis of interferon-β treatment in multiple sclerosisSemantic proximity Read ↗

Time course transcriptomics of IFNB1b drug therapy in multiple sclerosisSemantic proximity Read ↗

Long-Term Genome-Wide Blood RNA Expression Profiles Yield Novel Molecular Response Candidates for IFN-β-1b Treatment in Relapsing Remitting MSSemantic proximity Read ↗

Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevanceSemantic proximity Read ↗

A Novel Sensitive and Selective Bioassay for Human Type I InterferonsSemantic proximity Read ↗

Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosisSemantic proximity Read ↗

Genomic effects of IFN-beta in multiple sclerosis patients.Semantic proximity Read ↗

Multiplex analysis of expression of three IFNβ-induced genes in antibody-positive MS patientsSemantic proximity Read ↗

Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between PatientsSemantic proximity Read ↗

Myxovirus resistance protein A (MxA) polymorphism is associated with IFNβ response in Iranian multiple sclerosis patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.